Alcista
$13.97
Precio del escenario
$22.520
-0.169 (-0.75%)Al cierre
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
Elanco Animal Health Inc is a good buy right now due to its current price of $22.52, which is significantly below the median analyst price target of $32, indicating a potential upside of 31.3%. Additionally, the company has shown a strong gross margin of 48.17% in Q2 2026, reflecting solid profitability. The main risk is the negative trend in recent performance, with a 5-day change of -4.37%, which could indicate short-term volatility.
KeyBanc
$30
2026-08-06
KeyBanc
2026-08-06
Precio objetivo
$30
Citi
$34
2026-08-06
Citi
2026-08-06
Precio objetivo
$34
Morgan Stanley
$26
2026-07-22
Morgan Stanley
2026-07-22
Precio objetivo
$26
TD Cowen
$32
2026-06-18
TD Cowen
2026-06-18
Precio objetivo
$32
Morgan Stanley
$23
2026-05-15
Morgan Stanley
2026-05-15
Precio objetivo
$23
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Wall Street's Latest Ratings Overview

Elanco Animal Health Addresses Year-Round Pet Health Needs

Elanco's Pet Health Business Accelerates Growth Amid Seasonal Changes

Elanco to Announce Q3 2026 Financial Results on November 6

Elanco to Announce Q3 2026 Financial Results on November 6
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Elanco Animal Health Inc is a good buy right now due to its current price of $22.52, which is significantly below the median analyst price target of $32, indicating a potential upside of 31.3%. Additionally, the company has shown a strong gross margin of 48.17% in Q2 2026, reflecting solid profitability. The main risk is the negative trend in recent performance, with a 5-day change of -4.37%, which could indicate short-term volatility.
11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.